Moderna (MRNA) Tops Q4 EPS by 51c, Beats on Revenue
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
Moderna (NASDAQ: MRNA) reported Q4 EPS of ($2.11), $0.51 better than the analyst estimate of ($2.62). Revenue for the quarter came in at $678 million versus the consensus estimate of $662.84 million.
For earnings history and earnings-related data on Moderna (MRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
- H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
- H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
